Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer

doi:10.3748/wjg.v19.i21.3309

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 21

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5771)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

358

HTML

3625

Figures (1-2)

197

Tables (1-3)

214

Sum=4394

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

687

Download

690

Sum=1377

Jun 7, 2013 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jun 7, 2013; 19(21): 3309-3315
Published online Jun 7, 2013. doi: 10.3748/wjg.v19.i21.3309

Open in New Tab Full Size Figure Download Figure

Figure 1 Overall survival analysis according to the Kaplan-Meier method for patients in the surgery only group (n = 634), the capecitabine and oxaliplatin group (n = 214) and the 5-fluorouracil, folinic acid and oxaliplatin group (n = 48). Overall survival was higher in the capecitabine and oxaliplatin (XELOX) group vs the surgery only group (P = 0.069) and 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX6) groups (P = 0.022).

Open in New Tab Full Size Figure Download Figure

Figure 2 Overall survival analysis according to the Kaplan-Meier method for patients in the D2 surgery only group (n = 185) and in the D2 surgery plus capecitabine and oxaliplatin group (n = 185) after propensity score matched-pair adjustment. XELOX: Capecitabine and oxaliplatin.

Citation: Wu Y, Wei ZW, He YL, Schwarz RE, Smith DD, Xia GK, Zhang CH. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer. World J Gastroenterol 2013; 19(21): 3309-3315
URL: https://www.wjgnet.com/1007-9327/full/v19/i21/3309.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i21.3309